PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases.
Business Model:
Revenue: $0
Employees: 11-50
PanGenetics was acquired by
Abbott.
The acquisition happend on 2009-11-12.
Details of the transaction were not public
Address:
City: Utrecht
State: Utrecht
Zip:
Country: The Netherlands
PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases. PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employs a lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2008 | Series C | 5 | $35.1M |
Biogen Idec Crédit Agricole Edmond de Rothschild Private Equity Forbion Capital Partners Index Ventures Biogen Idec Crédit Agricole Edmond de Rothschild Private Equity Forbion Capital Partners Index Ventures |
9/2005 | Seed Round | 1 | $2M |
Index Ventures Index Ventures |
3/2006 | Series B | 3 | $15.6M |
ABN AMRO Fund Crédit Agricole Index Ventures ABN AMRO Fund Crédit Agricole Index Ventures |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|